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ABSTRACT
Background: Melatonin may reduce REM-sleep
behavior disorder (RBD) symptoms in Parkinson’s dis-
ease (PD), though robust clinical trials are lacking.
Objective: To assess the efﬁcacy of prolonged-release
(PR) melatonin for RBD in PD.
Methods: Randomized, double-blind, placebo-
controlled, parallel-group trial with an 8-week interven-
tion and 4-week observation pre- and postintervention
(ACTRN12613000648729). Thirty PD patients with rapid
eye movement sleep behavior disorder were random-
ized to 4 mg of prolonged-release melatonin (Circadin)
or matched placebo, ingested orally once-daily before
bedtime. Primary outcome was the aggregate of
rapid eye movement sleep behavior disorder incidents
averaged over weeks 5 to 8 of treatment captured by a
weekly diary. Data were included in a mixed-model
analysis of variance (n = 15 per group).
Results: No differences between groups at the pri-
mary endpoint (3.4 events/week melatonin vs. 3.6 pla-
cebo; difference, 0.2; 95% conﬁdence interval = −3.2
to 3.6; P = 0.92). Adverse events included mild head-
aches, fatigue, and morning sleepiness (n = 4 melato-
nin; n = 5 placebo).
Conclusion: Prolonged-release melatonin 4 mg did
not reduce rapid eye movement sleep behavior disor-
der in PD. © 2019 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Inter-
national Parkinson and Movement Disorder Society.
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Rapid eye movement (REM) sleep behavior disorder
(RBD) causes a loss of muscle atonia during REM
sleep, leading to dream enactment behaviors that are
frequently injurious to patients and their partners.1 Its
prevalence in adults is around 1%,1 compared to 20%
to 50% of people with Parkinson’s disease (PD).2,3
Treatment includes clonazepam or melatonin.3,4
Clonazepam is a long-acting benzodiazepine linked to
adverse outcomes,3,4 whereas its efﬁcacy for reducing
RBD in PD was recently challenged.5 Melatonin has a
safer proﬁle with milder side effects, such as headache
and morning sleepiness.2,4,6-9 Melatonin has a 30- to
50-minute elimination half-life.10 A prolonged-release
(PR) formulation has thus been recommended for RBD,
given that most REM sleep occurs later in the night.11
However, current guidelines are based on mainly case
series and small open-label studies.6,7,9,11-16 Only one
previous randomized controlled trial (RCT) assessed the
efﬁcacy of 3 mg of melatonin in just 8 subjects with
mixed neurological disorders, showing a modest
improvement on the clinical global impression (CGI)
and REM epochs without atonia.8 However, another
small RCT recently showed that 2 (n = 7) or 6 mg
(n = 9) of PR melatonin did not improve CGI versus pla-
cebo (n = 9) in subjects with clinically isolated RBD.17
No RCT has been conducted for RBD in PD. Moreover,
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there is need of an RBD-speciﬁc outcome that is free
from subjective interpretation by study assessors.4
We set out to assess the efﬁcacy of 4 mg of PR mela-
tonin on RBD severity using patient-reported diary
entries. We hypothesized that melatonin would reduce
RBD compared to placebo.
Materials and Methods
Design
A phase-II, randomized, double-blind, placebo-con-
trolled, parallel-group trial with an 8-week intervention
and 4 weeks of observation pre- and postintervention
(Supporting Information Fig. S1) was conducted at the
Woolcock Institute of Medical Research (Sydney,
Australia). The pre-observation weeks served for screen-
ing eligibility. The post-observation period assessed
whether the effects would persist.8,11 Ethical approval
was obtained from the Human Research Ethics Commit-
tees of the University of Sydney and Royal Prince Alfred
Hospital, Australia. The trial was prospectively registered
(ACTRN12613000648729) with its protocol published
online: anzctr.org.au/ACTRN12613000648729.aspx.
Participants
We set out to recruit 30 PD participants with video-
polysomnography (PSG)-conﬁrmed RBD. Supporting
Information Table S1 lists the eligibility criteria. All
participants gave written informed consent in accor-
dance with the Declaration of Helsinki.18
Randomization
Participants were randomized (1:1) using a computer-
ized blocked randomization sequence by the trial epide-
miologist (N.S.M.) not involved with recruitment or
assessment. The placebo was identical in appearance to
the melatonin. Independent pharmacists prepared identi-
cal treatment bottles based on the randomization
sequence that remained concealed to all other staff. Ran-
domization was performed by providing participants
with their respective bottles, which contained the exact
amount of study drug required. Masking was thereby
ensured for patients and staff giving the intervention,
assessing the outcomes, and analyzing the data.
Procedures
The intervention consisted of 4 mg (1 × 2 tables-2 mg)
of PR melatonin (Circadin) or 4 mg (1 × 2 tables-2 mg)
of matched placebo (lactose-monohydrate) produced by
Neurim Pharmaceuticals Inc. (Tel Aviv-Yafo, Israel). Par-
ticipants were instructed to ingest the trial drug orally,
once-daily, after food, within 1 hour before bedtime, for
8 weeks.
Participants completed the weekly CIRUS-RBD Ques-
tionnaire (wCIRUS-RBDQ; Supporting Information),
every morning about the preceding night. They were
instructed to record any instance of RBD as noted by
themselves and/or their partners (if applicable).
A video-PSG was performed within 12 months before
randomization and within weeks 5 to 8 of the treat-
ment period.
Participants wore a Philips Respironics Actiwatch
2 (Koninklijke Philips N.V., Amsterdam, Netherlands)
on the wrist least affected by PD19 and ﬁlled out an
associated diary for 1 week during baseline and again
within weeks 5 to 8 of treatment. Actigraphy was
scored manually using Philips Respironics Actiware-5
software (Koninklijke Philips N.V.).
The protocol included ﬁve monthly visits (Supporting
Information Fig. S1). Participants completed the RBD
Screening Questionnaire, Innsbruck RBD Inventory, and
RBD-Questionnaire Hong Kong, at visits 1, 2, 4, and
5. Secondary questionnaire outcomes (Supporting Infor-
mation Table S2) were completed at baseline and weeks
5 to 8 of treatment. During visit 2, ﬁnal eligibility was
assessed, followed by the CGI and International
Parkinson and Movement Disorder Society (MDS)-
UPDRS. Eligible participants were randomized at visit
2. During visit 3, a safety assessment was conducted, and
during visit 4, another CGI and MDS-UPDRS were per-
formed. During visit 5, a ﬁnal CGI was conducted.
Outcomes
The primary outcome was the difference in mean total
number of RBD events captured by the wCIRUS-RBDQ
item-4. The primary endpoint was taken as the aggregate
of all RBD incidents averaged over weeks 5 to 8 of treat-
ment. All other measures are regarded secondary in
importance (Supporting Information Table S2). A medi-
cal ofﬁcer assessed adverse events at each visit.
Analysis
Sample size was arbitrarily determined by our budget
and because no studies could be used to calculate sam-
ple size using our novel primary outcome. Assuming a
7% dropout, 28 patients would complete the trial. We
calculated that we would be 90% powered (α = 5%) to
detect a drop from an assumed 2.25 to 1.0 RBD events
per week (56% reduction) with an assumed standard
deviation of 1.0 on the primary outcome. Given that
only 1 subject dropped out, this study was powered to
detect the preset change in RBD symptoms. Patients
were analyzed in the group they were randomized
to. There were no interim analyses, and the trial
stopped when we recruited our intended sample size.
The primary and secondary outcomes derived from
the wCIRUS-RBDQ were analyzed by mixed-model
analyses of variance in SAS software (version 9.4; SAS
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Institute Inc., Cary, NC) using the patient as random
effects and drug randomization and time (weeks into
the trial) as ﬁxed effects. The primary endpoint was
compared between groups with a least means square
test within the interaction between time and treatment
(regardless of the main interactions). The model used
all interim measures to reduce measurement error
within patients. Subjects were categorized as treatment
responders (CGI = 1–3) or nonresponders (CGI ≥4) at
visit 4. The proportion of responders was compared
across groups using Fisher’s exact test. For all other
outcomes, the delta between visits 4 and 2 was com-
puted and compared between groups using two-sided
t tests or the Mann-Whitney U test using IBM-SPSS
software (version 25.0; IBM Corp., Armonk, NY) with
an alpha of 5%.
A post-hoc analysis was performed to assess whether
the outcomes were inﬂuenced by variations in bedtimes
(Supporting Information).8,20 Adherence in completing
the wCIRUS-RBDQ was determined by the percentage of
missing entries over the total amount of entries expected.
Results
Participants
Thirty-eight participants were screened between August
1, 2013 and October 5, 2017. Eight were deemed ineligi-
ble (Fig. 1). The remaining participants were randomized
to melatonin (n = 15) or placebo (n = 15). One partici-
pant on placebo dropped out in the ﬁrst month after
moving overseas. Two protocol violations occurred
whereby 2 participants with clinical and video-PSG-
conﬁrmed RBD were randomized into the melatonin
group who should not have been. One participant who
3 months after the study developed PD had subclinical
MDS diagnostic criteria at baseline,21 and another scored
zero RBD events on the wCIRUS-RBDQ. All data were
entered into the primary analysis based on an intention
to treat. Participants’ baseline characteristics are reported
in Supporting Information Table S3.
Outcomes
No reduction in RBD was found between groups (3.4
events/week melatonin vs. 3.6 placebo; absolute differ-
ence: 0.2; 95% conﬁdence interval [CI] = –3.2 to 3.6;
P = 0.92, Fig. 2A). Secondary outcomes also revealed
no difference for the number of nights in which RBD
was reported (2.1 nights/week melatonin vs. 1.8 pla-
cebo; difference, 0.35; 95% CI = –0.8 to 1.5; P = 0.56,
Fig. 2B) or change in the frequency of vivid dreams (2.4
dreams/week melatonin vs. 2.9 placebo; difference, –
0.6; 95% CI = –2.2 to 1.1; P = 0.49). RBD-related inju-
ries could not be analyzed, because only 5 participants
(3 melatonin, 2 placebo) reported an injury. Sensitivity
analysis without the participant in the melatonin group
who scored zero RBD events did not change our con-
clusions (P = 0.97; see Supporting Information).
The average sleep-onset latency on actigraphy
decreased with melatonin compared to placebo
(U = 12.0; Z = –3.17; P = 0.002; ŗ = 0.68). The 36-item
Short Form Survey subscale “Energy Fatigue” also
improved on melatonin compared to placebo (U = 53.5;
Z = –2.06; P = 0.040; ŗ = 0.39). No other differences
were found (Supporting Information Tables S4–S6).
Three participants (2 placebo, 1 melatonin) revealed
an apnea-hypopnea index >20 during their second
PSG.22 However, RBD with dream enactment was
observed in these subjects and clearly distinguishable
from apnoea-induced arousals.
Adverse events were mild and included headaches,
fatigue, light-headedness, and morning sleepiness (n = 4
melatonin, n = 5 placebo).9 The melatonin dosage of
1 participant was reduced to 2 mg after 3 weeks because
of light-headedness and morning sleepiness, as per proto-
col. None of the adverse events required further medical
attention.
An adherence of 99.0% was found for completing the
primary outcome, which remained above 97% for any
given week. No associations were found between bed-
time variability and treatment responses (Supporting
Information).
Discussion
This small, randomized, placebo-controlled, double-
blinded, parallel-group trial indicates that 4 mg of PR
melatonin is well tolerated, but not efﬁcacious in ame-
liorating self-reported RBD in PD.
FIG. 1. Trial proﬁle. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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These results challenge the current clinical assump-
tions on the efﬁcacy of melatonin for RBD,8,9 although
previous studies included small samples with a variety
of disorders, questioning their generalizability to
PD.6-9,11-14,23-25 The effects of prior trials were often
mixed, with several participants not responding to
FIG. 2. Primary and secondary wCIRUS-RBDQ outcome. Patient and partner reported dream enactment events were collected every day in weeklong
diary reports and then averaged in 4-week epochs that represent the four phases of the study (pretreatment, early and late treatment, and follow-up).
The primary endpoint of the study was the late treatment epoch (weeks 5–8). Panel (A) shows that there was no signiﬁcant difference between melato-
nin (in blue) and placebo (in red) on the number of RBD events (primary outcome; P for difference = 0.92). The absolute range of RBD events per week
underlying the data at baseline were 0 to 28 (28 being an outlier) for the melatonin group and 0 to 18 events per week for the placebo group. Panel
(B) shows that there was no signiﬁcant difference between groups on the number of nights in which a dream enactment event occurred RBD events
(secondary outcome 1; P for difference = 0.56). The error bars drawn are the standard errors. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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melatonin, even at dosages of up to 25 mg.14,15 A dis-
crepancy was also noted between the clinician’s subjec-
tive impression and objective changes on PSG.9,13
Previous ﬁndings in uncontrolled and unblinded studies
might thus be explained by the robust placebo effect we
report here.
Another strength of our study was the use of an RBD-
speciﬁc primary outcome (provided in the Supporting
Information) that allowed for adequate power by
recording daily entries and without assessor bias.23
However, the low sample size was not powered to
detect group differences on secondary outcomes. The
sample size was also too small to deﬁnitely rule out an
effect of melatonin for reducing RBD. Despite the ran-
domization, the groups differed on the primary out-
come at baseline.
The wCIRUS-RBDQ may not have captured all
RBD. This limitation is likely inherent to all studies
evaluating RBD, given that patients and their partners
are often not aware of the symptoms and there likely
exists night-to-night variability in frequency and
severity.
Not all subjects had bed partners (Supporting Informa-
tion), which may have limited their ability to notice
RBD.23 Studies are also encouraged to control for
pramipexole intake, which may impact on RBD.26
Finally, studies should consider recording actigraphy from
the most-affected arm in PD, given that it may show more
RBD.27
Importantly, our protocol can now be adopted to
test for the efﬁcacy of other RBD treatments, including
clonazepam and higher dosages or different formula-
tions of melatonin.28-32 Larger, multicentred RCT’s
are still warranted to assess the efﬁcacy of both drugs
for reducing RBD. Such trials should plan for observ-
ing strong placebo effects when using patient-reported
outcomes.
In conclusion, administration of melatonin may not
be efﬁcacious for reducing symptomatic RBD in PD.
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ABSTRACT
Objectives: We investigated retinal change and its
relationship with neurodegeneration markers in a pro-
dromal Parkinson cohort.
Methods: A total of 30 patients with idiopathic rapid
eye movement sleep behavior disorder were recruited.
Participants underwent olfactory testing, macular opti-
cal coherence tomography, microperimetry, contrast
sensitivity test, and brain N-(3-[18F]ﬂuoropropyl)-
2-carbomethoxy-3-(4-iodophenyl) nortropane positron
emission tomography. We measured the ganglion cell
complex thicknesses and investigated its correlation
with olfactory function and striatal dopamine trans-
porter availability. A linear mixed-effect model was
applied with adjustment for multiple comparisons.
Results: The parafoveal ganglion-cell-complex thick-
ness in this cohort lay between our healthy control
and drug-naïve Parkinson’s disease group data. Idio-
pathic rapid eye movement sleep behavior disorder
patients also had contrast sensitivity impairment as in
Parkinson’s disease with a nonsigniﬁcant change in
macular sensitivities. Macular ganglion cell complex
thickness correlated with olfactory scores and with
striatal dopamine transporter availabilities.
Conclusions: Macular ganglion cell complex thinning
may be a marker of neurodegeneration in prodromal
Parkinson’s disease. © 2019 International Parkinson
and Movement Disorder Society
Key Words: biomarker; idiopathic rapid eye move-
ment sleep behavior disorder; optical coherence
tomography; Parkinson’s disease; retina
Parkinson’s disease (PD) patients commonly encoun-
ter central vision abnormalities,1 peripheral vision
problems, and cortical level visuoperceptual disabilities,
including impaired facial emotional recognition.2,3
These visual symptoms can be observed from the very
early stages of the disease.4-6
The retina is similar to the brain in terms of cell com-
position, structure, and inﬂammatory and immunologic
reactions to insults.7,8 It also has dopaminergic cells
that express α-synuclein, and loss of retinal dopamine
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